Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose
Intravenous iron is commonly prescribed for treatment of iron deficiency, with modern formulations demonstrating an acceptable safety profile in the majority of patients. We report the case of a patient who was hospitalised with muscle pain, deteriorating mobility and multiple fractures following re...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-10-01
|
| Series: | JGH Open |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jgh3.12150 |
| _version_ | 1818722619789148160 |
|---|---|
| author | Wendy Fang Lawrence P McMahon Stephen Bloom Mayur Garg |
| author_facet | Wendy Fang Lawrence P McMahon Stephen Bloom Mayur Garg |
| author_sort | Wendy Fang |
| collection | DOAJ |
| description | Intravenous iron is commonly prescribed for treatment of iron deficiency, with modern formulations demonstrating an acceptable safety profile in the majority of patients. We report the case of a patient who was hospitalised with muscle pain, deteriorating mobility and multiple fractures following repeated ferric carboxymaltose infusions. Investigations revealed severe hypophosphatemia with serum phosphate of 0.27 mmol/L, 25‐hydroxyvitamin D (25OHD) level of 32 nmol/L and insufficiency fractures of the sacrum and L5 transverse process. The patient's hypophosphatemia was corrected with several infusions of intravenous phosphate, as well as oral phosphate and calcitriol, with subsequent resolution of her muscle aches, back pain and immobility. The risk of persistent hypophosphatemia and osteomalacia may be higher with iron carboxymaltose than other iron formulations and a transient increase in intact fibroblast growth factor‐23 with reduced renal tubular phosphate absorption has been postulated as the key mechanism. This risk appears increased by repeated iron infusions, underlying malnutrition, hypophosphatemia at baseline, vitamin D deficiency, hyperparathyroidism or anti‐resorptive medication use. The true risk and incidence of hypophosphatemia need to be clarified so that appropriate monitoring, prevention and treatment strategies can be developed. |
| first_indexed | 2024-12-17T20:57:31Z |
| format | Article |
| id | doaj.art-c994f66c9862408f8d1adfb80565f133 |
| institution | Directory Open Access Journal |
| issn | 2397-9070 |
| language | English |
| last_indexed | 2024-12-17T20:57:31Z |
| publishDate | 2019-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | JGH Open |
| spelling | doaj.art-c994f66c9862408f8d1adfb80565f1332022-12-21T21:32:49ZengWileyJGH Open2397-90702019-10-013543844010.1002/jgh3.12150Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltoseWendy Fang0Lawrence P McMahon1Stephen Bloom2Mayur Garg3Department of Gastroenterology Eastern Health Melbourne Victoria AustraliaDepartment of Eastern Health Clinical School Monash University Melbourne Victoria AustraliaDepartment of Gastroenterology Eastern Health Melbourne Victoria AustraliaDepartment of Gastroenterology Eastern Health Melbourne Victoria AustraliaIntravenous iron is commonly prescribed for treatment of iron deficiency, with modern formulations demonstrating an acceptable safety profile in the majority of patients. We report the case of a patient who was hospitalised with muscle pain, deteriorating mobility and multiple fractures following repeated ferric carboxymaltose infusions. Investigations revealed severe hypophosphatemia with serum phosphate of 0.27 mmol/L, 25‐hydroxyvitamin D (25OHD) level of 32 nmol/L and insufficiency fractures of the sacrum and L5 transverse process. The patient's hypophosphatemia was corrected with several infusions of intravenous phosphate, as well as oral phosphate and calcitriol, with subsequent resolution of her muscle aches, back pain and immobility. The risk of persistent hypophosphatemia and osteomalacia may be higher with iron carboxymaltose than other iron formulations and a transient increase in intact fibroblast growth factor‐23 with reduced renal tubular phosphate absorption has been postulated as the key mechanism. This risk appears increased by repeated iron infusions, underlying malnutrition, hypophosphatemia at baseline, vitamin D deficiency, hyperparathyroidism or anti‐resorptive medication use. The true risk and incidence of hypophosphatemia need to be clarified so that appropriate monitoring, prevention and treatment strategies can be developed.https://doi.org/10.1002/jgh3.12150adverse effectsferric carboxymaltosegastrointestinal bleedinghypophosphatemiaintravenous ironiron deficiency |
| spellingShingle | Wendy Fang Lawrence P McMahon Stephen Bloom Mayur Garg Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose JGH Open adverse effects ferric carboxymaltose gastrointestinal bleeding hypophosphatemia intravenous iron iron deficiency |
| title | Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose |
| title_full | Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose |
| title_fullStr | Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose |
| title_full_unstemmed | Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose |
| title_short | Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose |
| title_sort | symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose |
| topic | adverse effects ferric carboxymaltose gastrointestinal bleeding hypophosphatemia intravenous iron iron deficiency |
| url | https://doi.org/10.1002/jgh3.12150 |
| work_keys_str_mv | AT wendyfang symptomaticseverehypophosphatemiaafterintravenousferriccarboxymaltose AT lawrencepmcmahon symptomaticseverehypophosphatemiaafterintravenousferriccarboxymaltose AT stephenbloom symptomaticseverehypophosphatemiaafterintravenousferriccarboxymaltose AT mayurgarg symptomaticseverehypophosphatemiaafterintravenousferriccarboxymaltose |